{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:03:30Z","timestamp":1791583410013,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1053\/j.seminhematol.2024.05.003","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T21:36:30Z","timestamp":1715722590000},"page":"245-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The pediatric approach to Hodgkin lymphoma"],"prefix":"10.1053","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9454-0857","authenticated-orcid":false,"given":"Mallorie B.","family":"Heneghan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Belsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Milgrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Forlenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2024.05.003_bib0001","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program Cancer Stat Facts: Hodgkin Lymphoma [cited April 19, 2024]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html."},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0002","doi-asserted-by":"crossref","first-page":"851","DOI":"10.6004\/jnccn.2023.0040","article-title":"Adolescent and young adult (AYA) oncology, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"Bhatia","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26321","article-title":"Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: a population-based case-control study","volume":"64","author":"Peckham-Gregory","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0004","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/sj.bjc.6603999","article-title":"Hodgkin's lymphoma and infection: findings from a UK case-control study","volume":"97","author":"Newton","year":"2007","journal-title":"British J Cancer"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0005","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0140-6736(91)90943-J","article-title":"Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease","volume":"337","author":"Pallesen","year":"1991","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10204665","article-title":"Hodgkin lymphoma: a special microenvironment","volume":"10","author":"Opinto","year":"2021","journal-title":"J Clin Med"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0007","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1200\/JCO.23.01115","article-title":"Spatially resolved tumor microenvironment predicts treatment outcomes in relapsed\/refractory Hodgkin lymphoma","volume":"42","author":"Aoki","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0008","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood.2021011941","article-title":"A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma","volume":"139","author":"Johnston","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0009","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1158\/2643-3230.BCD-22-0128","article-title":"Molecular evolution of classic Hodgkin lymphoma revealed through whole-genome sequencing of Hodgkin and Reed Sternberg cells","volume":"4","author":"Maura","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0010","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/cncr.20189","article-title":"Familial aggregation of Hodgkin lymphoma and related tumors","volume":"100","author":"Goldin","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0011","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood.2022016056","article-title":"Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma","volume":"141","author":"Flerlage","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0012","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0013","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/10428194.2020.1839651","article-title":"LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma","volume":"62","author":"Moerdler","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0014","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0015","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3109\/10428194.2010.525724","article-title":"Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988-2005: an analysis of 21 734 cases","volume":"51","author":"Bazzeh","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0016","first-page":"01655","article-title":"International Prognostic Score for Nodular Lymphocyte\u2013Predominant Hodgkin Lymphoma","volume":"23","author":"Binkley","year":"2024","journal-title":"Journal of Clinical Oncology:JCO"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0017","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2015.65.3469","article-title":"Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the children's oncology group","volume":"34","author":"Appel","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0018","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study","volume":"117","author":"Castellino","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0019","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.1002\/cam4.3138","article-title":"Treatment patterns and outcomes in adolescents and young adults with Hodgkin lymphoma in pediatric versus adult centers: An IMPACT Cohort Study","volume":"9","author":"Gupta","year":"2020","journal-title":"Cancer Med"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2019.02.011","article-title":"Timing of first-in-child trials of FDA-approved oncology drugs","volume":"112","author":"Neel","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0021","unstructured":"Brentuximab Vedotin 2018 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/brentuximab-vedotin#:~:text=On%20March%2020%2C%202018%2C%20the%20Food%20and%20Drug,classical%20Hodgkin%20lymphoma%20%28cHL%29%20in%20combination%20with%20chemotherapy."},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0022","unstructured":"FDA approves brentuximab vedotin in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma, 2022."},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0023","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/pbc.20546","article-title":"Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study","volume":"46","author":"Tebbi","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0024","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/pbc.24279","article-title":"Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group","volume":"59","author":"Tebbi","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0025","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1002\/cncr.31519","article-title":"Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: a report from the Children's Oncology Group","volume":"124","author":"Keller","year":"2018","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0026","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","volume":"23","author":"Mauz-Korholz","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0027","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1470-2045(23)00019-0","article-title":"Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study","volume":"24","author":"Mauz-Korholz","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0028","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2008-10-184143","article-title":"A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425","volume":"114","author":"Schwartz","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0029","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.16014","article-title":"Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group","volume":"187","author":"Kelly","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0031","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin's lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0032","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0033","first-page":"2023","author":"Castellino","year":"2023"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0034","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/jama.1902.62480030024001h","article-title":"Cases of sarcoma and of Hodgkin's disease treated by exposures to X-rays\u2014a preliminary report","volume":"XXXVIII","author":"Pusey","year":"1902","journal-title":"J Am Med Assoc"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0035","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood.V59.3.455.455","article-title":"The management of stage I\u2013II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience","volume":"59","author":"Hoppe","year":"1982","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0036","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1200\/JCO.20.01186","article-title":"Impact of risk-adapted therapy for pediatric hodgkin lymphoma on risk of long-term morbidity: a report from the childhood cancer survivor study","volume":"39","author":"Oeffinger","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0037","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijrobp.2016.01.053","article-title":"A comparative evaluation of normal tissue doses for patients receiving radiation therapy for Hodgkin lymphoma on the childhood cancer survivor study and recent children's oncology group trials","volume":"95","author":"Zhou","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0038","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO.20.03286","article-title":"Excellent outcome for pediatric patients with high-risk Hodgkin lymphoma treated with brentuximab vedotin and risk-adapted residual node radiation","volume":"39","author":"Metzger","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0039","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13935","article-title":"Assessment of radiation doses delivered to organs at risk among patients with early-stage favorable Hodgkin lymphoma treated with contemporary radiation therapy","volume":"3","author":"Pinnix","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0040","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based review on the use of proton therapy in lymphoma from the particle therapy cooperative group (PTCOG) lymphoma subcommittee","volume":"99","author":"Tseng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0041","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.ijrobp.2023.06.362","article-title":"Radiotherapy utilization and outcomes on a contemporary trial for pediatric high-risk Hodgkin lymphoma study","volume":"117","author":"Hoppe","year":"2023","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0042","doi-asserted-by":"crossref","first-page":"55","DOI":"10.14338\/IJPT-21-00012.1","article-title":"Evaluating disparities in proton radiation therapy use in AHOD1331, a Contemporary Children's Oncology Group Trial for advanced-stage Hodgkin lymphoma","volume":"8","author":"Mailhot Vega","year":"2022","journal-title":"Int J Part Ther"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0043","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1097\/HS9.0000000000000329","article-title":"Risk and response adapted treatment guidelines for managing first relapsed and refractory classical hodgkin lymphoma in children and young people. Recommendations from the EuroNet pediatric hodgkin lymphoma group","volume":"4","author":"Daw","year":"2020","journal-title":"Hemasphere"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0044","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/bmt.2015.177","article-title":"A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma","volume":"50","author":"Satwani","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0045","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/pbc.25205","article-title":"Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory\/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report","volume":"62","author":"Trippett","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0046","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.2008.20.3778","article-title":"Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report","volume":"27","author":"Cole","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0047","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(18)30426-1","article-title":"Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial","volume":"19","author":"Cole","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0048","first-page":"2075","article-title":"Nivolumab and brentuximab vedotin with or without bendamustine for R\/R Hodgkin lymphoma in children, adolescents, and young adults","volume":"141","author":"Harker-Murray","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0049","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.7515","volume":"41","author":"Harker-Murray","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0050","article-title":"Results from an intergroup randomized phase II study of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed\/refractory classic Hodgkin lymphoma: a trial of the ECOG-ACRIN Research Group (E4412)","volume":"142","author":"Diefenbach","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0051","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(22)00318-0","article-title":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","volume":"10","author":"Herrera","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0052","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0053","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0054","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.3324\/haematol.2023.282780","article-title":"Effect of cumulative dose of brentuximab vedotin maintenance in relapsed\/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes","volume":"108","author":"Wagner","year":"2023","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0055","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/bloodadvances.2022009323","article-title":"Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed\/refractory Hodgkin lymphoma","volume":"7","author":"Forlenza","year":"2023","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0056","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-153968","article-title":"CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients","volume":"138","author":"Hucks","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0057","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0058","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0059","doi-asserted-by":"crossref","first-page":"9306","DOI":"10.1182\/blood-2022-157748","article-title":"CD25, soluble CD25, and CCL17 as potential predictors of clinical response to camidanlumab tesirine in patients with relapsed\/refractory classical Hodgkin lymphoma","volume":"140","author":"Dyczkowski","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0060","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein Barr virus\u2013specific cytotoxic T lymphocytes expressing the anti-CD30\u03b6 artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease","volume":"110","author":"Savoldo","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0061","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0062","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/S2352-3026(21)00349-5","article-title":"Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials","volume":"9","author":"Kahn","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0063","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2010-05-285379","article-title":"BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0064","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-189652","article-title":"AHOD2131: a randomized phase 3 response-adapted trial comparing standard therapy with immuno-oncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma","volume":"142","author":"Henderson","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0065","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/jama.2012.5847","article-title":"Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma","volume":"307","author":"Metzger","year":"2012","journal-title":"Jama"},{"key":"10.1053\/j.seminhematol.2024.05.003_bib0066","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2020-136422","article-title":"SWOG S1826: a phase III, randomized study of nivolumab plus AVD or brentuximab vedotin plus AVD in patients with newly diagnosed advanced stage classical Hodgkin lymphoma","volume":"136","author":"Herrera","year":"2020","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T09:04:46Z","timestamp":1726823086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0037196324000611"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.05.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pediatric approach to Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}